个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Inhibition of VEGF agents therapy with or without docetaxel as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials

| 认领 | 导出 |

文献详情

资源类型：
WOS体系：

收录情况： ◇ SCIE

作者：
Lei, Naijun[1] * ; Song, Zhengfang[1] ;
机构： [1]Sichuan Canc Hosp & Inst, Dept Urinary Surg, Chengdu 610041, Sichuan, Peoples R China
出处：
ISSN：

关键词： Docetaxel Inhibition of VEGF Castration-resistant prostate cancer Randomized controlled trial Meta analysis

语种：
外文
WOS：
中科院(CAS)分区：
出版当年[2014]版：
大类 | 4 区 医学
小类 | 4 区 医学：研究与实验
最新[2023]版：
大类 | 3 区 医学
小类 | 3 区 医学：研究与实验
JCR分区：
出版当年[2014]版：
Q3 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1 MEDICINE, RESEARCH & EXPERIMENTAL

影响因子： 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者：
第一作者机构： [1]Sichuan Canc Hosp & Inst, Dept Urinary Surg, Chengdu 610041, Sichuan, Peoples R China
推荐引用方式(GB/T 7714)：
Lei Naijun,Song Zhengfang.Inhibition of VEGF agents therapy with or without docetaxel as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials[J].INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE.2014,34:S26-S26.
APA：
Lei, Naijun&Song, Zhengfang.(2014).Inhibition of VEGF agents therapy with or without docetaxel as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials.INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE,34,
MLA：
Lei, Naijun,et al."Inhibition of VEGF agents therapy with or without docetaxel as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials".INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE 34.(2014):S26-S26

相关文献

[1]多西他赛单药或联合血管内皮生长因子抑制剂治疗去势抵抗性前列腺癌疗效和安全性的Meta分析 [2]Docetaxel-based therapy with and without antiangiogenic agents as first-line chemotherapy for castration-resistant prostate cancer: A meta-analysis of nine randomized controlled trials. [3]Comparison of Systemic Treatments for Metastatic Castration-Resistant Prostate Cancer After Docetaxel Failure: A Systematic Review and Network Meta-analysis. [4]The second docetaxel rechallenge for metastatic castration-resistant prostate cancer: a case report [5]Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer [6]Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: view of evidence-based medicine [7]Neuroendocrine differentiation predicts the therapeutic efficacy of abiraterone and docetaxel as first-line therapy in metastatic castration-resistant prostate cancer [8]Oral Acetyl-L-Carnitine treatment in hepatic encephalopathy: View of evidence-based medicine [9]Evaluation of the Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis. [10]AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy.

资源点击量：52808 今日访问量：0 总访问量：4561 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号